IPGP: Inverse Head And Shoulders detected on 25 Sep 2026

IPGP is forming an inverse head-and-shoulders pattern after reporting double-digit year-over-year revenue growth for the third consecutive quarter with Q2 revenue reaching $279 million, up 11%. The current price of $77.42 sits above the right shoulder, positioned 11.54% above the 52-week low yet down 50.31% from the 52-week high, suggesting recovery momentum. With a structure score of 11.0, volume score of 10.0, and breakout score of 13.0 (moderate quality), the pattern targets $81.32 conservatively. The setup shows neutral RSI at 46.13, positive MACD momentum at 0.6144, and volume ratio of 0.97 aligning with recent averages—conditions favor a clean reversal if support at $74.51 holds.

IPG Photonics announced a binding offer to acquire Lumibird Medical, which is expected to expand its medical laser platform and increase its addressable medical market by approximately $1 billion. The company is making significant progress in strategic growth areas including battery manufacturing, additive manufacturing, and semiconductor applications, with emerging growth products now accounting for 58% of total revenue. Bookings remained strong with book-to-bill above 1 for the third consecutive quarter, indicating sustained demand. However, the company faces ongoing headwinds from tariffs, which are expected to impact gross margin by approximately 150 basis points in Q3 2026. Citi lowered its price target on IPGP to $137 from $150 but keeps a Buy rating. The post-earnings pullback created this inverse H&S structure amid solid fundamentals but macro headwinds.

A successful breakout above $81.32 would align with the conservative measured move target, requiring volume confirmation above the 0.97 recent average to signal institutional accumulation. Invalidation occurs decisively below the key support at $74.51; a break there would negate the pattern and suggest a lower-bound retest. With a win probability of 62.73%, the pattern indicates roughly 2-in-3 odds of upside follow-through. The pattern suggests reaching $81.32 would represent a 5.0% gain from current levels. Sustained momentum above resistance near $75.54 will be critical; the high beta of 1.87 means IPGP will amplify broader market moves—both up and down.

Tariff headwinds are expected to impact gross margin by approximately 150 basis points in Q3 2026, which could pressure near-term profitability. Advanced Solutions revenue decreased 9% year-over-year driven by lower revenue in micromachining and defense, signaling uneven segment performance. The stock's high beta of 1.87 amplifies volatility in a rotating market—any broad tech pullback will exacerbate downside risk. RSI at 46.13 indicates no overbought condition, but the 3-month loss of 29.77% reflects significant recent selling pressure; a failed breakout at $81.32 could restart that downtrend. The Lumibird Medical acquisition adds integration risk, and tariff impact quantification in Q3 guidance may trigger further volatility. Monitor Q3 earnings for margin compression confirmation.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.